WO2004089974A1 - Process for the preparation of macrocyclic compounds by ruthenium complex catalysed metathesis reaction - Google Patents
Process for the preparation of macrocyclic compounds by ruthenium complex catalysed metathesis reaction Download PDFInfo
- Publication number
- WO2004089974A1 WO2004089974A1 PCT/EP2004/003216 EP2004003216W WO2004089974A1 WO 2004089974 A1 WO2004089974 A1 WO 2004089974A1 EP 2004003216 W EP2004003216 W EP 2004003216W WO 2004089974 A1 WO2004089974 A1 WO 2004089974A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- alkyl
- group
- cycloalkyl
- preparation
- Prior art date
Links
- 0 CC1N(*)C(*)C(*)N1C Chemical compound CC1N(*)C(*)C(*)N1C 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/22—Organic complexes
- B01J31/2204—Organic complexes the ligands containing oxygen or sulfur as complexing atoms
- B01J31/2208—Oxygen, e.g. acetylacetonates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/22—Organic complexes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/22—Organic complexes
- B01J31/2265—Carbenes or carbynes, i.e.(image)
- B01J31/2269—Heterocyclic carbenes
- B01J31/2273—Heterocyclic carbenes with only nitrogen as heteroatomic ring members, e.g. 1,3-diarylimidazoline-2-ylidenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
- C07F15/0046—Ruthenium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
- C07K1/088—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing other elements, e.g. B, Si, As
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/50—Redistribution or isomerisation reactions of C-C, C=C or C-C triple bonds
- B01J2231/54—Metathesis reactions, e.g. olefin metathesis
- B01J2231/543—Metathesis reactions, e.g. olefin metathesis alkene metathesis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/821—Ruthenium
Definitions
- the invention relates to an improved process for the preparation of macrocyclic compounds of formula I
- the macrocyclic compounds of formula I are known from the International patent application WO 00/59929.
- the compounds disclosed there are highly active agents for the treatment of hepatitis C virus infections.
- the methods for the preparation of these compounds include many synthetic steps, which involve protection and deprotection of certain reactive groups and leads to an insufficient overall yield.
- the International patent application suggests to form the macrocycle via an olefin metathesis using a rutheniiun based catalyst, selected from the following formulae
- the problem underlying the present invention was to provide a process which allows the manufacture of the macrocyclic compounds of formula I in a technical scale with lower amounts of catalyst, better turn-over rates, higher yields and improved room-time yield.
- the invention relates to an improved process for the preparation of a macrocyclic compound of formula I
- R 2 is a hydroxy group, a leaving group or a group of formula II
- W is CH orN
- R 21 is H, halo, C ⁇ -6 alkyl, C 3 , 6 cycloalkyl, C ⁇ -6 haloalkyl, C ⁇ . 6 alkoxy, C 3-6 cycloalkoxy, hydroxy, or N(R 23 ) 2 , wherein each R 23 is independently H, C ⁇ -6 alkyl or C 3-6 cycloalkyl;
- R 22 is H, halo, C ⁇ -6 alkyl, C 3-6 cycloalkyl, C ⁇ -6 haloalkyl, C ⁇ -6 thioalkyl , C ⁇ -6 alkoxy, C 3- 6 cycloalkoxy, C 2-7 alkoxyalkyl, C 3-6 cycloalkyl, C 6 or 10 aryl or Het, wherein Het is a five-, six-, or seven-membered saturated or unsaturated heterocycle containing from one to four heteroatoms selected from nitrogen, oxygen and sulfur; said cycloalkyl, aryl or Het being substituted with R 24 , wherein
- R 24 is H, halo, C ⁇ -6 alkyl, C 3-6 cycloalkyl, C ⁇ -6 alkoxy, C 3-6 cycloalkoxy, N0 2 ,
- R 25 is independently: H, C ⁇ -6 alkyl or C 3-6 cycloalkyl; or R 24 is NH-C(0)-OR 26 wherein R 26 is C ⁇ -6 alkyl or C 3-6 cycloalkyl;
- R 28 is H, halo or C ⁇ -6 alkyl, preferably H
- R 3 is hydroxy, NH , or a group of formula -NH-R 31 , wherein R 31 is C 6 or 10 aryl, heteroaryl, -C(0)-R 32 , -C(0)-NHR 32 or -C(0)-OR 32 , wherein R 32 is C ⁇ -6 alkyl or C 3-6 cycloalkyl;
- D is a 3 to 7-atom saturated alkylene chain
- A is an amide of formula -C(0)-NH-R 5 , wherein R 5 is selected from the group consisting of: C ⁇ -8 alkyl, C 3-6 cycloalkyl, C 6 or ⁇ o aryl, C 7- ⁇ 6 aralkyl; and S0 2 R 5A wherein R 5A is C ⁇ -8 alkyl, C 3- cycloalkyl or ⁇ C ⁇ -6 alkyl-C 3-7 cycloalkyl ⁇ , or
- A is a carboxylic acid or a pharmaceutically acceptable salt or ester thereof
- R >2 , ⁇ R3 and A are as defined hereinbefore; and D' represents a 3 to 7-atom saturated alkylene chain;
- X 1 and X 2 each independently represent an anionic ligand;
- L represents a neutral electron donor ligand;
- R 4 represents a C ⁇ -6 alkyl, C 2-6 alkenyl or C 6- ⁇ aryl-C ⁇ -6 alkyl group.
- - 6 alkyl means an alkyl group or radical having 1 to 6 carbon atoms
- the last named group is the radical attachment point, for example, "thioalkyl” means a monovalent radical of the formula HS-Alk-.
- conventional definitions of terms control and conventional stable atom valences are presumed and achieved in all formulas and groups.
- C ⁇ _ 6 alkyl as used herein, either alone or in combination with another substituent, means acyclic, straight or branched chain alkyl substituents containing from 1 to six carbon atoms and includes, for example, methyl, ethyl, propyl, butyl, hexyl, 1- ' methylethyl, 1-methylpropyl, 2-methylpropyl, and 1,1-dimethylethyl.
- C 3 . 6 cycloalkyl as used herein, either alone or in combination with another substituent, means a cycloalkyl substituent containing from three to six carbon atoms and includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- saturated alkylene chain means a divalent alkyl substituent derived by the removal of one hydrogen atom from each end of a saturated straight or branched chain aliphatic hydrocarbon and includes, for example, CH 2 CH 2 C(CH 3 ) 2 CH 2 CH 2 -.
- C ⁇ -6 alkoxy as used herein, either alone or in combination with another substituent, means the substituent C ⁇ -6 alkyl-O-. wherein alkyl is as defined above containing up to six carbon atoms.
- Alkoxy includes methoxy, ethoxy, propoxy, 1- methylethoxy, butoxy and 1,1-dimethylethoxy. The latter substituent is known commonly as tert-butoxy.
- C 3-6 cycloalkoxy as used herein, either alone or in combination with another substituent, means the substituent C 3-6 cycloalkyl-O- containing from 3 to 6 carbon atoms.
- C 2-7 alkoxy-C ⁇ -6 alkyl as used herein, means the substituent C 2-7 alkyl-0-C ⁇ -6 alkyl wherein alkyl is as defined above containing up to six carbon atoms.
- halo as used herein means a halogen substituent selected from bromo, chloro, fluoro or iodo.
- haloalkyl as used herein means as used herein, either alone or in combination with another substituent, means acyclic, straight or branched chain alkyl substituents having one or more hydrogens substituted for a halogen selected from bromo, chloro, fluoro or iodo.
- thioalkyl as used herein means as used herein, either alone or in combination with another substituent, means acyclic, straight or branched chain alkyl substituents containing a thiol (HS) group as a substituent.
- HS thiol
- An example of a thioalkyl group is a thiopropyl, e.g., HS-CH 2 CH 2 CH - is one example of a thiopropyl group.
- C 6 or o aryl as used herein, either alone or in combination with another substituent, means either an aromatic monocyclic system containing 6 carbon atoms or an aromatic bicyclic system containing 10 carbon atoms.
- aryl includes a phenyl or a naphthyl - ring system.
- C 7- ⁇ 6 aralkyl as used herein, either alone or in combination with another substituent, means an aryl as defined above linked through an alkyl group, wherein alkyl is as defined above containing from 1 to 6 carbon atoms.
- Aralkyl includes for example benzyl, and butylphenyl.
- Het as used herein, either alone or in combination with another substituent, means a monovalent substituent derived by removal of a hydrogen from a five-, six-, or seven-membered saturated or unsaturated (including aromatic) heterocycle containing carbon atoms and from one to four ring heteroatoms selected from nitrogen, oxygen and sulfur.
- suitable heterocycles include: tetrahydrofuran, thiophene, diazepine, isoxazole, piperidine, dioxane, morpholine, pyrimidine or
- Het also includes a heterocycle as defined above fused to one or more other cycle be it a heterocycle or any other cycle.
- One such examples includes thiazolo[4,5-b]- pyridine.
- Het the term “heteroaryl” as used herein precisely defines an unsaturated heterocycle for which the double bonds form an aromatic system. Suitable example of hetero aromatic system include: quinoline, indole, pyridine,
- esters of the compound of formula I in which any of the carboxyl functions of the molecule, but preferably the carboxy terminus, is replaced by an alkoxycarbonyl function:
- the R moiety of the ester is selected from alkyl (e.g. methyl, ethyl, /z-propyl, t- butyl, H-butyl); alkoxyalkyl (e.g. methoxymethyl); alkoxyacyl (e.g. acetoxymethyl); aralkyl (e.g. benzyl); aryloxyalkyl (e.g. phenoxymethyl); aryl (e.g. phenyl), optionally substituted with halogen, C ⁇ - alkyl or C ⁇ - alkoxy.
- alkyl e.g. methyl, ethyl, /z-propyl, t- butyl, H-butyl
- alkoxyalkyl e.g. methoxymethyl
- alkoxyacyl e.g. acetoxymethyl
- aralkyl e.g. benzyl
- aryloxyalkyl e.g. phen
- esters are usually hydrolyzed in vivo when injected in a mammal and transformed into the acid form of the compound of formula I.
- any alkyl moiety present advantageously contains 1 to 16 carbon atoms, particularly 1 to 6 carbon atoms.
- Any aryl moiety present in such esters advantageously comprises a phenyl group.
- esters may be a C ⁇ _ ⁇ 6 alkyl ester, an unsubstituted benzyl ester or a benzyl ester substituted with at least one halogen, C ⁇ - 6 alkyl, C ⁇ -6 alkoxy, nitro or trifluoromethyl.
- pharmaceutically acceptable salt includes those derived from pharmaceutically acceptable bases. Examples of suitable bases include choline, ethanolamine and ethylenediamine. Na + , K + , and Ca salts are also contemplated to be within the scope of the invention (also see Pharmaceutical salts, Birge, S.M. et al., J. Pharm. Sci., (1977), 66, 1-19, incorporated herein by reference).
- reaction conditions and reaction times may vary depending on the particular reactants used. Unless otherwise specified, solvents, temperatures, pressures, and other reaction conditions may be readily selected by one of ordinary skill in the art. Specific procedures are provided in the Synthetic Examples section.
- R 5 and R ⁇ each independently represent a hydrogen atom or a C ⁇ - 6 alkyl, C 2-6 alkenyl, C 6- ⁇ 2 aryl or C 6- ⁇ 2 aryl-C ⁇ -6 alkyl group, preferably a hydrogen atom; or R , 5 and R together form a double bond; and
- R 7 and R 8 each independently represent a hydrogen atom or a C ⁇ -6 alkyl, C 2-6 alkenyl, C 6- ⁇ aryl or C 6- ⁇ 2 aryl-C ⁇ -6 alkyl group, preferably a phenyl group which may be substituted by one, two or three groups selected from halogen atom, C ⁇ -6 alkyl and C ⁇ -6 alkoxy groups;
- X 1 and X 2 each independently represent a halogen atom, preferably a chlorine atom; and
- R 4 represents a C ⁇ -6 alkyl group, preferably a branched C 3-6 alkyl group.
- ruthenium catalysts of formula IV wherein the nitro group is attached in the para-position with respect to the point of attacliment of the alkoxy group R 4 -O-.
- R and R represent a trimethylphenyl group, in particular mesityl group.
- Furthennore preferred is a process for the preparation of a macrocyclic compound of fomiula I according to the present invention, wherein the metathesis reaction is carried out in the presence of a diluent in a temperature range from 40 to 120 °C, preferably from 60 to 100 °C, in particular at about 80 °C.
- the methathesis reaction is carried out in the presence of a diluent selected from the group consisting of alkanes, such as n-pentane, n-hexane or n-heptane, aromatic hydrocarbons, such as benzene, toluene or xylene, and chlorinated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane or dichloroethane.
- alkanes such as n-pentane, n-hexane or n-heptane
- aromatic hydrocarbons such as benzene, toluene or xylene
- chlorinated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane or dichloroethane.
- a process for the preparation of a macrocyclic compound of formula I wherein the molar ratio of the diene compound of formula III to the catalyst of formula TV ranges from 1000 : 1 to 100 : 1, preferably from 500 : 1 to 110 : 1, in particular
- the process for the preparation of a macrocyclic compound of formula I is carried out at a ratio of the diene compound of formula III to diluent in the range from 1 : 400 by weight to 1 : 25 by weight, preferably from 1 : 200 by weight to 1 : 50 by weight, in particular from 1 : 150 by weight to 1 : 75 by weight.
- R 2 is a group of fonnula II
- W is N
- R 21 is H, Ci- 6 alkyl, C ⁇ -6 alkoxy, hydroxy, chloro;
- R 22 is H, C ⁇ -6 thioalkyl, C ⁇ -6 alkoxy, phenyl or Het selected from the group consisting
- R 24 is H, C ⁇ -6 alkyl, NH-R 25 , NH-C(0)-R 25 ; NH-C(O)-NH-R 25 , wherein each R 25 is independently: H, C ⁇ -6 alkyl, or C 3-6 cycloalkyl; or NH-C(0)-OR ,26 ⁇ , wherein R 26 0 i •s C ⁇ -6 alkyl:
- R 28 is H, bromine or methyl, preferably H or R 2 is a leaving group of formula -OS 0 2 -R 27 , wherein R 27 is selected from p-tolyl, p-bromophenyl, p-nitrophenyl, methyl, trifluoromethyl, perfluorobutyl and 2,2,2-trifluoroethyl.
- Ri moiety is a group of formula (i);
- A is a carboxylic acid or a pharmaceutically acceptable salt or ester thereof, most preferably COOH;
- W is N
- R 21 is C ⁇ - 3 alkoxy
- R 22 i ⁇ s NH-(CO) m -(C ⁇ - alkyi) or NH-(CO) m -(C 3-6 cycloalkyl), with m being 0 or 1, preferably 0;
- R 28 is H or methyl, preferably H
- R 3 is NH-C(0)-OR 10 , wherein R 10 is butyl, cyclobutyl or cyclopentyl; D is a 5-atom saturated alkylene chain; and
- A is a carboxylic acid or a pharmaceutically acceptable salt or ester thereof.
- R ,28 is Methyl and the bond from position 14 to the cyclopropyl group is syn to the COOH, said 13, 14 double bond is cis, and R 13 , R 4 and R 2 are defined as follows table 2:
- a specific representative compound from the table 1 is Compound No. 822.
- Another aspect of the present invention is a process for the preparation of a macrocyclic compound of formula IA
- Ri, R , R >27 and A are as defined hereinbefore; and D' represents a 3 to 7-atom saturated alkylene chain; in the presence of the ruthenium catalyst of formula IV as defined above; and
- R >21 , R ", R" and W are as defined hereinbefore.
- hydroxyl-substituted quinoline compounds of fonnula are known, e.g., from WO 00/59929, WO 00/09543 and WO 00/09558, U.S. Patent 6,323,180 Bl and US Patent 6,608,027 Bl.
- the catalysts of formula IV can be prepared according to the method described by K. Grela et al., Angew. Chem. Int. Ed. 2002, 41, No. 21 pp. 4038-4040, the complete disclosure of which being incorporated herein by reference.
- the catalysts of formula TV are preferably prepared by reacting a 2-alkoxy-nitro-stilbene compound of formula V with a ruthenium compound of formula VI in the presence of transition metal salts such as Cu (I) salts in particular CuCl according to the following reaction scheme:
- Boc la lb la (416,3 g, 1.8 mol) is dissolved in Tetrahydrofurane (THF, 2.08 1) and cooled with ice to -5 - -10°C.
- Mesylchloride (392 g, 3.4 mol) and N-methylpyrrolidine (429 g, 5 mol) is added and the mixture stirred for 1 Y_ h at -5°C.
- the mixture is washed with water and heated up to reflux.
- Dioxane (2,08 1) is poured in and the THF is distilled off. After cooling down to room temperature, diisopropylethylamine (DIPEA, 233 g, 1.8 mol) is added and the mixture is heated to reflux.
- DIPEA diisopropylethylamine
- the ruthenium catalyst is prepared in accordance with the method disclosed by K. Grela et al., Angew. Chem. Int. Ed. 2002, 41, No. 21 pp. 4038-4040 as follows: 0.8 ml (8 mmol) 2-iodopropane is added to a stirred mixture 1.1 g (8 mmol) of dry powdered potassium carbonate521 mg of cesium carbonate, 668 mg (4 mmol) 2-hydroxy- 5-nitrobenzaldehyde and 25 mL dimethylformaide (DMF). After stirring at ambient temperature for 24 hours DMF is removed in vacuo and residue is poured into 50 ml of water and extracted four times with 25 ml of tert-butylmethyl ether (TBME).
- TBME tert-butylmethyl ether
- Tetrakishydroxymethylphosphoniumchlorid (80%, 98.7 mmol) is dissolved in isopropanol (35 ml) under a nitrogen atmosphere. Then 12.1 g (98.7 mmol) of a 45% KOH solution is added within 5 min while the solution is cooled (temperature 20 - 25°C). After stirring the suspension for another 30 min under nitrogen, the mixture is filtered and the inorganic residue is washed with 20 ml of degassed isopropanol. The combined isopropanol solution is stored under a nitrogen atmosphere until use.
- the suspension is cooled to 5°C, the precipitate is filtered and washed with ethyl acetate/n-heptane (or ethyl acetate/methylcyclohexane) and dried in vacuo to yield: 60 - 70% of 4 as white crystals. If necessary (quality) the product can be re- crystallized from ethyl acetate/methylcyclohexane.
- the mixture is stirred for further 60 min at a temperature of 40-45°C. Further 80 ml of water are added at 40- 45°C over a period of at least 30 min and the mixture is st rred for another 60 min at the same temperature.
- the suspension is cooled to 20-25 °C and strrred at this temperature for 1 h. After filtration the precipitate is washed three times by 20 ml of water and dried in vacuo at 35°C (slight stream of N2) to yield 17.7 - 18.7 g of crade 5 (90-95%).
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006500076A JP2007523833A (en) | 2003-04-10 | 2004-03-26 | Process for producing macrocyclic compounds by ruthenium complex-catalyzed metathesis reaction |
EP04723554A EP1615949A1 (en) | 2003-04-10 | 2004-03-26 | Process for the preparation of macrocyclic compounds by ruthenium complex catalysed metathesis reaction |
CA002521835A CA2521835A1 (en) | 2003-04-10 | 2004-03-26 | Process for the preparation of macrocyclic compounds by ruthenium complex catalysed metathesis reaction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46187903P | 2003-04-10 | 2003-04-10 | |
US60/461,879 | 2003-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004089974A1 true WO2004089974A1 (en) | 2004-10-21 |
Family
ID=33159834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/003216 WO2004089974A1 (en) | 2003-04-10 | 2004-03-26 | Process for the preparation of macrocyclic compounds by ruthenium complex catalysed metathesis reaction |
Country Status (7)
Country | Link |
---|---|
US (1) | US20040248779A1 (en) |
EP (1) | EP1615949A1 (en) |
JP (1) | JP2007523833A (en) |
KR (1) | KR20060008877A (en) |
CN (1) | CN1771257A (en) |
CA (1) | CA2521835A1 (en) |
WO (1) | WO2004089974A1 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006033878A1 (en) * | 2004-09-17 | 2006-03-30 | Boehringer Ingelheim International, Gmbh | Process for preparing macrocyclic hcv protease inhibitors |
EP1673385A1 (en) * | 2003-09-22 | 2006-06-28 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
WO2007003135A1 (en) * | 2005-07-04 | 2007-01-11 | Zheng-Yun Zhan | Ruthenium complex ligand, ruthenium complex, carried ruthenium complex catalyst and the preparing methods and the use thereof |
US7268211B2 (en) | 2003-12-08 | 2007-09-11 | Boehringer Ingelheim International Gmbh | Removal of ruthenium by-product by supercritical fluid processing |
US7368452B2 (en) | 2003-04-18 | 2008-05-06 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
WO2009124853A1 (en) * | 2008-04-11 | 2009-10-15 | F. Hoffmann-La Roche Ag | New ruthenium complexes as catalysts for metathesis reactions |
WO2009137432A1 (en) * | 2008-05-09 | 2009-11-12 | Boehringer Ingelheim International Gmbh | A method for preparing macrocycles |
US7781474B2 (en) | 2006-07-05 | 2010-08-24 | Intermune, Inc. | Inhibitors of hepatitis C virus replication |
US7829665B2 (en) | 2005-07-25 | 2010-11-09 | Intermune, Inc. | Macrocyclic inhibitors of hepatitis C virus replication |
EP2364984A1 (en) | 2005-08-26 | 2011-09-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
US8119592B2 (en) | 2005-10-11 | 2012-02-21 | Intermune, Inc. | Compounds and methods for inhibiting hepatitis C viral replication |
CN102421786A (en) * | 2009-05-07 | 2012-04-18 | 弗·哈夫曼-拉罗切有限公司 | Process for the preparation of ruthenium metathesis complex catalysts |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
US8314141B2 (en) | 1996-10-18 | 2012-11-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
US8420596B2 (en) | 2008-09-11 | 2013-04-16 | Abbott Laboratories | Macrocyclic hepatitis C serine protease inhibitors |
US8937041B2 (en) | 2010-12-30 | 2015-01-20 | Abbvie, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
US8951964B2 (en) | 2010-12-30 | 2015-02-10 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
US8993595B2 (en) | 2009-04-08 | 2015-03-31 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
US9284307B2 (en) | 2009-08-05 | 2016-03-15 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors |
US9328108B2 (en) | 2011-10-28 | 2016-05-03 | Janssen Pharmaceuticals, Inc. | Process for preparing an intermediate of the macrocyclic protease inhibitor TMC 435 |
US9333204B2 (en) | 2014-01-03 | 2016-05-10 | Abbvie Inc. | Solid antiviral dosage forms |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
US10201541B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7148347B2 (en) * | 2003-04-10 | 2006-12-12 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic compounds |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
DE602005025855D1 (en) * | 2004-01-21 | 2011-02-24 | Boehringer Ingelheim Pharma | MACROCYCLIC PEPTIDES WITH EFFECT TO THE HEPATITIS C VIRUS |
RU2006136084A (en) * | 2004-03-15 | 2008-04-27 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | METHOD FOR PRODUCING MICROCYCLIC COMPOUNDS |
EP1753775B1 (en) * | 2004-05-25 | 2012-12-26 | Boehringer Ingelheim International GmbH | Process for preparing acyclic hcv protease inhibitors |
DE102004033312A1 (en) * | 2004-07-08 | 2006-01-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Continuous metathesis process with ruthenium catalysts |
CA2578428A1 (en) | 2004-09-17 | 2006-03-30 | Boehringer Ingelheim International Gmbh | Ring-closing metathesis process in supercritical fluid |
DE102005002336A1 (en) * | 2005-01-17 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for conducting continuous olefin-ring closure metathesis in compressed carbon dioxide |
EP2332963A3 (en) | 2005-03-08 | 2011-11-16 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic compounds |
ES2364426T3 (en) * | 2005-09-09 | 2011-09-02 | Boehringer Ingelheim International Gmbh | METAL PROCESS WITH CLOSURE OF THE RING FOR THE PREPARATION OF MACROCYCLIC PEPTIDES. |
MX2009012093A (en) | 2007-05-10 | 2010-01-25 | Intermune Inc | Novel peptide inhibitors of hepatitis c virus replication. |
KR20100118991A (en) | 2008-02-04 | 2010-11-08 | 아이데닉스 파마슈티칼스, 인코포레이티드 | Macrocyclic serine protease inhibitors |
WO2010033443A1 (en) * | 2008-09-17 | 2010-03-25 | Boehringer Ingelheim International Gmbh | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
CN102596201A (en) | 2009-10-30 | 2012-07-18 | 贝林格尔.英格海姆国际有限公司 | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
BR112015007887A2 (en) | 2012-10-08 | 2017-07-04 | Abbvie Inc | compounds useful for making hcv protease inhibitors |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1022282A2 (en) * | 1999-01-22 | 2000-07-26 | Aventis Research & Technologies GmbH & Co. KG | Homo- and hetero metal alkylidene complexes of ruthenium with N-heterocyclic carbene ligands, and their use as highly active and selective catalysts for olefin metathesis |
WO2000059929A1 (en) * | 1999-04-06 | 2000-10-12 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
US7148347B2 (en) * | 2003-04-10 | 2006-12-12 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic compounds |
-
2004
- 2004-03-26 CN CNA2004800096390A patent/CN1771257A/en active Pending
- 2004-03-26 EP EP04723554A patent/EP1615949A1/en not_active Withdrawn
- 2004-03-26 KR KR1020057019240A patent/KR20060008877A/en not_active Application Discontinuation
- 2004-03-26 WO PCT/EP2004/003216 patent/WO2004089974A1/en active Application Filing
- 2004-03-26 JP JP2006500076A patent/JP2007523833A/en active Pending
- 2004-03-26 CA CA002521835A patent/CA2521835A1/en not_active Abandoned
- 2004-03-30 US US10/813,344 patent/US20040248779A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1022282A2 (en) * | 1999-01-22 | 2000-07-26 | Aventis Research & Technologies GmbH & Co. KG | Homo- and hetero metal alkylidene complexes of ruthenium with N-heterocyclic carbene ligands, and their use as highly active and selective catalysts for olefin metathesis |
WO2000059929A1 (en) * | 1999-04-06 | 2000-10-12 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
Non-Patent Citations (2)
Title |
---|
GRELA KAROL ET AL: "A highly efficient ruthenium catalyst for metathesis reactions.", ANGEWANDTE CHEMIE (INTERNATIONAL ED. IN ENGLISH) 4 NOV 2002, vol. 41, no. 21, 4 November 2002 (2002-11-04), pages 4038 - 4040, XP002288511, ISSN: 0570-0833 * |
WESKAMP T ET AL: "A NOVEL CLASS OF RUTHENIUM CATALYSTS FOR OLEFIN METATHESIS", ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, VERLAG CHEMIE. WEINHEIM, DE, vol. 37, no. 18, 1998, pages 2490 - 2493, XP000984751, ISSN: 0570-0833 * |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8314141B2 (en) | 1996-10-18 | 2012-11-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
US7368452B2 (en) | 2003-04-18 | 2008-05-06 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
EP1673385B1 (en) * | 2003-09-22 | 2011-03-02 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
EP1673385A1 (en) * | 2003-09-22 | 2006-06-28 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
US7268211B2 (en) | 2003-12-08 | 2007-09-11 | Boehringer Ingelheim International Gmbh | Removal of ruthenium by-product by supercritical fluid processing |
US7375218B2 (en) | 2004-09-17 | 2008-05-20 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic HCV protease inhibitors |
WO2006033878A1 (en) * | 2004-09-17 | 2006-03-30 | Boehringer Ingelheim International, Gmbh | Process for preparing macrocyclic hcv protease inhibitors |
WO2007003135A1 (en) * | 2005-07-04 | 2007-01-11 | Zheng-Yun Zhan | Ruthenium complex ligand, ruthenium complex, carried ruthenium complex catalyst and the preparing methods and the use thereof |
US7829665B2 (en) | 2005-07-25 | 2010-11-09 | Intermune, Inc. | Macrocyclic inhibitors of hepatitis C virus replication |
EP2364984A1 (en) | 2005-08-26 | 2011-09-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
EP2366704A1 (en) | 2005-08-26 | 2011-09-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
US8119592B2 (en) | 2005-10-11 | 2012-02-21 | Intermune, Inc. | Compounds and methods for inhibiting hepatitis C viral replication |
US7781474B2 (en) | 2006-07-05 | 2010-08-24 | Intermune, Inc. | Inhibitors of hepatitis C virus replication |
WO2009124853A1 (en) * | 2008-04-11 | 2009-10-15 | F. Hoffmann-La Roche Ag | New ruthenium complexes as catalysts for metathesis reactions |
US7939668B2 (en) | 2008-04-11 | 2011-05-10 | Roche Palo Alto Llc | Ruthenium complexes as catalysts for metathesis reactions |
WO2009137432A1 (en) * | 2008-05-09 | 2009-11-12 | Boehringer Ingelheim International Gmbh | A method for preparing macrocycles |
US8420596B2 (en) | 2008-09-11 | 2013-04-16 | Abbott Laboratories | Macrocyclic hepatitis C serine protease inhibitors |
US8642538B2 (en) | 2008-09-11 | 2014-02-04 | Abbvie, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
US9309279B2 (en) | 2008-09-11 | 2016-04-12 | Abbvie Inc. | Macrocyclic hepatitis C serine protease inhibitors |
US8993595B2 (en) | 2009-04-08 | 2015-03-31 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
CN102421786A (en) * | 2009-05-07 | 2012-04-18 | 弗·哈夫曼-拉罗切有限公司 | Process for the preparation of ruthenium metathesis complex catalysts |
CN102421786B (en) * | 2009-05-07 | 2016-01-20 | 弗·哈夫曼-拉罗切有限公司 | The preparation method of ruthenium transposition composite catalyst |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
US9284307B2 (en) | 2009-08-05 | 2016-03-15 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors |
US8951964B2 (en) | 2010-12-30 | 2015-02-10 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
US8937041B2 (en) | 2010-12-30 | 2015-01-20 | Abbvie, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
US10201541B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US9328108B2 (en) | 2011-10-28 | 2016-05-03 | Janssen Pharmaceuticals, Inc. | Process for preparing an intermediate of the macrocyclic protease inhibitor TMC 435 |
US9333204B2 (en) | 2014-01-03 | 2016-05-10 | Abbvie Inc. | Solid antiviral dosage forms |
US9744170B2 (en) | 2014-01-03 | 2017-08-29 | Abbvie Inc. | Solid antiviral dosage forms |
US10105365B2 (en) | 2014-01-03 | 2018-10-23 | Abbvie Inc. | Solid antiviral dosage forms |
Also Published As
Publication number | Publication date |
---|---|
JP2007523833A (en) | 2007-08-23 |
CN1771257A (en) | 2006-05-10 |
US20040248779A1 (en) | 2004-12-09 |
CA2521835A1 (en) | 2004-10-21 |
EP1615949A1 (en) | 2006-01-18 |
KR20060008877A (en) | 2006-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004089974A1 (en) | Process for the preparation of macrocyclic compounds by ruthenium complex catalysed metathesis reaction | |
JP4231524B2 (en) | Process for producing macrocyclic compounds | |
JP4654239B2 (en) | Method for preparing macrocyclic dipeptide suitable for treatment of hepatitis C virus infection | |
US7951773B2 (en) | Ring-closing metathesis process for the preparation of macrocyclic peptides | |
EP1863833B1 (en) | Process for preparing macrocyclic compounds | |
JP2008513452A (en) | Ring closure metathesis in supercritical fluids | |
JP2002524250A (en) | Catalytic complex with carben ligand | |
JP4785748B2 (en) | Novel metathesis ruthenium catalyst | |
JP5414889B2 (en) | Method for producing ruthenium metathesis complex catalyst | |
WO2008009671A1 (en) | Process for the preparation of a tetrahydro-1h-azepines | |
AU2012232960A1 (en) | Process for preparing macrocyclic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004723554 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4119/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 171293 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2521835 Country of ref document: CA Ref document number: 2006500076 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048096390 Country of ref document: CN Ref document number: 1020057019240 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004723554 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057019240 Country of ref document: KR |